1. The Biology Behind BCL2 as a Target in Myeloma

2. Apoptosis

3. BCL2 Family of Proteins

4. Apoptotic Pathways

5. Apoptosis Initiation

6. Mechanisms of BCL2 Family Dysregulation

7. Patterns of Expression of Key BCL2-Family Proteins in Patients With Multiple Myeloma

8. Cytokines Regulate Expression of BCL2-Family Proteins BCL2, BCLXL, and MCL1

9. BCL2 as a Therapeutic Target

10. Venetoclax

11. Mechanisms of Resistance

12. Combining Anti-BCL2 Therapy with Dexamethasone

13. Predicting Sensitivity to Anti-BCL2 Therapy

14. Myeloma, t(11;14), and BCL2

15. Bcl2 Inhibition and t(11;14)

16. Venetoclax Phase 1 in RRMM: Design

17. Venetoclax Phase 1 in RRMM: Key Patient Characteristics

18. Venetoclax Phase 1 in RRMM: Safety

19. Venetoclax Phase 1 in RRMM: Response

20. Venetoclax Phase 1 in RRMM: TTP and DOR

21. Venetoclax in Phase 1 in RRMM: BCL2: BCL2L1 Ratio

22. Venetoclax Phase 1 in RRMM: Responses by BCL2:BCL2L1 Ratio Among t(11;14)-Positive Patients

23. Enhancing the BCL2 Inhibition Strategy

24. Venetoclax and Bortezomib: Background

25. Venetoclax + Bortezomib Phase 1 in RRMM: Design

26. Venetoclax + Bortezomib Phase 1 in RRMM: Key Patient Characteristics

27. Venetoclax + Bortezomib Phase 1 in RRMM: Safety

28. Venetoclax + Bortezomib Phase 1 in RRMM: Response

29. Venetoclax + Bortezomib Phase 1 in RRMM: Response By Lines of Therapy

30. Venetoclax + Bortezomib Phase 1 in RRMM: TTP and DOR

31. Venetoclax + Bortezomib Phase 1 in RRMM: BCL2 Gene Expression and Clinical Response

32. Enhancing the Bcl2 Inhibition Strategy

33. Ongoing Evaluation of Anti-BCL2 Therapy in Patients with Multiple Myeloma

34. Developing Biomarkers to Predict Response to Anti-BCL2 Therapy

35. Summary

36. Abbreviations

37. Abbreviations (cont)

38. Abbreviations (cont)